DEVELOPMENT OF A VESIVAS IMMUNOSIMILAR FORMULATION
$569,807N43FY2021AINIH
Molecular Express, Inc., Rancho Dominguez CA
Investigators
Abstract
The overall goal of this project is to use VesiVax® platform technology to develop effective immunosimilar formulations of an AS01/AS01b.
View original record on NIH RePORTER →